EUCTR2012-001876-13-EE进行中（未招募）不适用
A Phase III, open, randomized, controlled, multicenter study to assess the immunogenicity and reactogenicity of GSK Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered alone as compared to MenACWY-TT co-administered with a licensed viral vaccine or co-administered with a licensed viral vaccine and GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) (Boostrix) in female adolescents and young adults at 9-25 years of age. - MenACWY-TT-054
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects and subjects’ parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
- •A female between, and including, 9 and 25 years of age at the time of the first vaccination.
- •Written informed consent obtained from parents/guardian of the subject and written informed assent obtained from the subject if the subject is less than legal age, or written informed consent obtained from the subject if the subject has achieved legal age. The legal age will be determined according to local regulations in each participating country.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •–Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •-has practiced adequate contraception for 30 days prior to vaccination, and
- •-has a negative pregnancy test on the day of vaccination, and
- •-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1300
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 325
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Child in care
- •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will be =10 mg/day prednisone or equivalent. Inhaled and topical steroids are allowed.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after each study dose of vaccine(s), with the exception of licensed inactivated influenza vaccine.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational product or a non-investigational vaccine/product.
- •Previous vaccination with a meningococcal polysaccharide or conjugate vaccine within the last 10 years.
- •History of meningococcal disease since birth.
- •History of serious allergic reaction following any other DTP-containing vaccine or any component of the study vaccines.
- •History of encephalopathy within seven days of administration of a previous pertussis antigen-containing vaccine that is not attributable to another identifiable cause.
- •Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus-toxoid containing vaccine should not receive Boostrix unless at least 10 years have elapsed since the last dose of tetanus-toxoid containing vaccine.
- •Previous vaccination with a tetanus-toxoid containing vaccine within the previous five years.
- •Temperature of = 40.5°C (105°F) within 48 hours of receipt of a previous dose of DTP vaccine (diphtheria-tetanus-whole cell pertussis [DTPw] and/or diphtheria-tetanus-acellular pertussis [DTaP]), not due to another identifiable cause.
- •Collapse or shock-like state within 48 hours of receipt of a previous dose of DTP vaccine.
- •Seizures with or without fever within three days of a previous dose of DTP vaccine.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, based on medical history and history directed physical examination.
- •A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
- •History of any allergic disease/reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
- •Progressive neurologic disorder, unstable neurologic conditions, uncontrolled epilepsy or progressive encephalopathy.
- •History of any neurologic disorders or seizures. A history of ADHD or depression or a history of a single, simple febrile seizure does not exclude a subject.
- •Major congenital defects or serious chronic illness.
- •Previous history of Guillain-Barré Syndrome.
- •Bleeding disorders, such as hemophilia or thrombocytopenia, or subjects on anti-coagulant therapy.
- •Acute disease and/or fever at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity & safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlersHealthy volunteers (for active immunization against N. meningitidis serogroups A, C, W-135 and Y when given as a booster dose for the MenC and MenY antigens and as a priming dose for the MenA and MenW-135 antigens in toddlers 12 to 18 months of age who were primed in infancy with Hib-MenCY-TT and Pediarix® at 2, 4, and 6 months of age)MedDRA version: 18.0Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOSSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10070124Term: Neisseria meningitidis test positiveSystem Organ Class: 100000004848EUCTR2012-002401-22-Outside-EU/EEAGlaxoSmithKline Biologicals1,558
进行中（未招募）
1 期
A phase III, open, randomized, controlled, multicentre, primary & booster study to demonstrate the non-inferiority of the MenC & Hib immune responses of GSK Biologicals’ Hib-MenC vaccine co-administered with Infanrix™ penta versus NeisVac-C™ co-administered with Infanrix™ hexa when given as 2 primary doses at 3, 5 m of age & prior to a booster dose at 11 m, as well as the immunogenicity of the Hib-MenC vaccine given as a booster at 11 m & the persistence of antibodies prior to the booster dose. - Hib-MenC-TT-014; Hib-MenC-TT-015 BST: 014EUCTR2005-005421-59-FIGlaxoSmithKline Biologicals709
进行中（未招募）
不适用
on-inferiority of meningococcal vaccine GSK134612 versus Mencevax™ in 11-17 year-old subjectsMeningococcal diseaseMedDRA version: 14.1Level: LLTClassification code 10027275Term: Meningococcal infection, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000282-20-Outside-EU/EEAGlaxoSmithKline Biologicals1,025
进行中（未招募）
不适用
A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years - MenACWY-TT-037Primary immunization of healthy subjects aged 11 through 17 years against meningococcal serogroups A, C, W 135 and Y and/or hepatitis A and hepatitis B diseasesEUCTR2006-005999-41-SEGlaxoSmithKline Biologicals600
进行中（未招募）
不适用
A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years - MenACWY-TT-037Primary immunization of healthy subjects aged 11 through 17 years against meningococcal serogroups A, C, W 135 and Y and/or hepatitis A and hepatitis B diseasesEUCTR2006-005999-41-DKGlaxoSmithKline Biologicals600